.Pharmacolibrary.Drugs.ATC.R.R03AK11 .Pharmacolibrary.Drugs.ATC.R.R03AK11| name: | FormoterolAndFluticasone |
| ATC code: | R03AK11 | route: | inhalation |
| n-compartments | 2 |
Formoterol and fluticasone is a fixed-dose combination medication consisting of formoterol, a long-acting beta2-adrenergic agonist (LABA), and fluticasone propionate, an inhaled corticosteroid (ICS), used in the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is approved in several regions as a combination inhaler for regular use in adults and adolescents.
Estimates for healthy adult population after inhalation as published pharmacokinetic studies for the combination under ATC R03AK11 are lacking; values are approximated based on literature of each individual component when given as an inhaled combination.
Latorre, M, et al., & Paggiaro, P (2015). Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulmonary pharmacology & therapeutics 30 44–50. DOI:10.1016/j.pupt.2014.10.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25445928